Kou Erwen, Zhang Xiaobei, Dong Baiping, Wang Bo, Zhu Yuanjie
Department of Dermatology, Naval Medical Center, Naval Medical University, Shanghai 200052, China.
Department of Pharmacy, Naval Medical Center, Naval Medical University, Shanghai 200052, China.
Life (Basel). 2024 Jan 23;14(2):164. doi: 10.3390/life14020164.
Histamine receptor antagonists, which can bind to specific histamine receptors on target cells, exhibit substantial therapeutic efficacy in managing a variety of histamine-mediated disorders. Notably, histamine H1 and H2 receptor antagonists have been extensively investigated and universally acknowledged as recommended treatment agents for numerous allergic diseases and acid-related disorders, respectively. Historically, the combination of H1 and H2 receptor antagonists has been considered a classic treatment strategy, demonstrating relatively superior efficacy compared with single-drug therapies in the treatment of diverse histamine-mediated diseases. The latest emerging studies have additionally suggested the underlying roles of histamine and H1R and H2R in the development of anxiety disorders, arthritic diseases, and postexercise hypotension. Nevertheless, there is still a lack of systematic reviews on the clinical efficacy of combination therapy, greatly limiting our understanding of its clinical application. Here, we present a comprehensive overview of the current knowledge and perspectives regarding the combination of H1 and H2 histamine receptor antagonists in various histamine-mediated disorders. Furthermore, we critically analyze the adverse effects and limitations associated with combination therapy while suggesting potential solutions. Our review can offer a systematic summary and promising insights into the in-depth and effective application of the combination of H1 and H2 receptor antagonists.
组胺受体拮抗剂能够与靶细胞上的特定组胺受体结合，在治疗多种组胺介导的疾病方面具有显著的治疗效果。值得注意的是，组胺H1和H2受体拮抗剂已得到广泛研究，并分别被普遍公认为众多过敏性疾病和酸相关疾病的推荐治疗药物。从历史上看，H1和H2受体拮抗剂的联合使用一直被视为一种经典的治疗策略，在治疗多种组胺介导的疾病方面，与单药治疗相比显示出相对更高的疗效。最新出现的研究还表明，组胺以及H1R和H2R在焦虑症、关节炎疾病和运动后低血压的发生发展中具有潜在作用。然而，目前仍缺乏关于联合治疗临床疗效的系统评价，这极大地限制了我们对其临床应用的理解。在此，我们全面概述了目前关于H1和H2组胺受体拮抗剂联合使用在各种组胺介导疾病中的知识和观点。此外，我们批判性地分析了联合治疗相关的不良反应和局限性，同时提出了潜在的解决方案。我们的综述可为H1和H2受体拮抗剂联合使用的深入有效应用提供系统总结和有前景的见解。
